ArticleDiabetes, obesity & metabolism2019

Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.

Elisabetta Patorno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.